Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 24, 2022
Document Information [Line Items]
Document Type	10-Q/A
Entity Registrant Name	GreenLight Biosciences Holdings, PBC
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-Q/A (“Amendment”) is being filed to correct our original Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 (the “Initial Form 10-Q”) filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2022. This Amendment amends Items 1 and 2 of the Initial Form 10-Q and no other items in the Initial Form 10-Q are amended hereby. The Amendment includes the Company’s restated condensed consolidated statement of operations for the three months ended March 31, 2022 and 2021 to correct an error related to the classification of operating expenses associated with general and administrative expense and research and development expense for the three months ended March 31, 2022, and to correct an error related to Net Loss per Share for the three months ended March 31, 2021. The condensed consolidated statement of operations for the three months ended March 31, 2022 and 2021, Notes 1 and 14 of the condensed consolidated financial statements, and the Results of Operations portion of Item 2 have been amended as a result of the correction of the foregoing errors. This restatement does not have any material impact on the Company's statement of financial positions, net loss, cash flows, liquidity, and capital resources.  In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (“Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officers are filed as exhibits to this filing. These errors were identified by the Company subsequent to the filing of the Initial Form 10-Q on May 16, 2022 and not in a timely manner by the Company's financial review process. Management has reassessed its evaluation of the effectiveness of its internal control over financial reporting as of March 31, 2022 and has concluded that there were and continues to be material weaknesses in the Company’s disclosure controls and procedures including internal controls over financial reporting. For the Company’s plan to remediate the material weaknesses, see Part I – Item 4. Controls and Procedures of this Amendment No. 1. Except as described above, the Amendment does not modify or update the disclosures presented in, or exhibits to, the Initial Form 10-Q. The Amendment continues to speak as of the date of the Initial Form 10-Q. Furthermore, the Amendment does not reflect events occurring after the filing of the Initial Form 10-Q.
Entity Central Index Key	0001822691
Document Quarterly Report	true
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	001-39894
Entity Tax Identification Number	85-1914700
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	200 Boston Avenue
Entity Address, City or Town	Medford
Entity Address, State or Province	MA
City Area Code	617
Local Phone Number	616-8188
Entity Address, Postal Zip Code	02155
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	GRNA
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		123,199,202
Entity Bankruptcy Proceedings, Reporting Current	true
Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock for $11.50 per share
Trading Symbol	GRNAW
Security Exchange Name	NASDAQ